We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock
FNCH

Delisted

FNCH was delisted on the 24th of May, 2024.

Back to rankings

43 hedge funds and large institutions have $16.8M invested in Finch Therapeutics Group, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less funds holding

Funds holding: 46 → 43 (-3)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

40% less capital invested

Capital invested by funds: $28M → $16.8M (-$11.2M)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
0.74%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
9
Reduced
11
Closed
7
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
SW
SVB Wealth
Massachusetts
+$587K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$247K
3
Millennium Management
Millennium Management
New York
+$69.2K
4
VF
Virtu Financial
New York
+$35.2K
5
BCM
Bridgeway Capital Management
Texas
+$26.1K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$216K
2
E
Ergoteles
New York
-$104K
3
Citadel Advisors
Citadel Advisors
Florida
-$70K
4
Morgan Stanley
Morgan Stanley
New York
-$62.1K
5
BFM
Boothbay Fund Management
New York
-$40.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$2.96M – – –
AMC
2
Avenir Management Company
New York
$2.78M – – –
BG
3
Baupost Group
Massachusetts
$1.88M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.69M – – –
BL
5
Bleichroeder LP
New York
$1.35M – – –
LSAG
6
Lake Street Advisors Group
New Hampshire
$1.23M – – –
TA
7
TRB Advisors
New York
$952K – – –
MP
8
MSD Partners
New York
$649K – – –
SW
9
SVB Wealth
Massachusetts
$423K +$587K +8,435 New
IC
10
Ikarian Capital
Texas
$397K -$216K -3,099 -28%
OMC
11
Oasis Management Company
Cayman Islands
$376K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$351K +$247K +3,558 +103%
AI
13
Aperture Investors
New York
$322K -$34.6K -498 -7%
BP
14
Ballentine Partners
Massachusetts
$240K – – –
Millennium Management
15
Millennium Management
New York
$202K +$69.2K +995 +33%
PCP
16
Proficio Capital Partners
Massachusetts
$185K – – –
BlackRock
17
BlackRock
New York
$117K +$8.55K +123 +6%
BCM
18
Bridgeway Capital Management
Texas
$107K +$26.1K +376 +21%
LCM
19
Laurion Capital Management
New York
$97K – – –
Renaissance Technologies
20
Renaissance Technologies
New York
$68K +$4.38K +63 +5%
SCM
21
SCS Capital Management
Massachusetts
$64K – – –
Goldman Sachs
22
Goldman Sachs
New York
$43K -$20.4K -293 -25%
Northern Trust
23
Northern Trust
Illinois
$42K +$25.5K +367 +77%
State Street
24
State Street
Massachusetts
$41K – – –
BFM
25
Boothbay Fund Management
New York
$40K -$40.2K -578 -42%
1
2

FNCH Hedge Fund Activity: Q3 2022 in Review

43 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q3 2022, worth a combined $16.8M — down 40% from $28M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of FNCH and 4 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was SVB Wealth, opening a new position worth an estimated $587K. The largest seller was Ikarian Capital, cutting an estimated $216K.

  • 43 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q3 2022, down from 46 in Q2 2022.
  • Funds reported $16.8M of Finch Therapeutics Group, Inc. Common Stock stock for Q3 2022, down 40% quarter-over-quarter.
  • 4 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q3 2022 and 7 closed out, a net change of -3 holders.
  • The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q3 2022 was SVB Wealth, an estimated $587K added.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q3 2022 was Ikarian Capital, an estimated $216K sold.

Based on aggregated 13F filings for Q3 2022.